Does Tufts Health Plan Cover Vyvanse?

What Is Vyvanse and Why Does Coverage Get Complicated?

Vyvanse is a prodrug stimulant converted in the body to d-amphetamine. The FDA approved lisdexamfetamine in 2007 for ADHD and in 2015 for moderate-to-severe binge eating disorder in adults. Because it is a Schedule II controlled substance, every insurer, including Tufts, applies stricter utilization management than they do for non-controlled medications.

The complexity compounds because Tufts Health Plan is not a single product. It operates several distinct lines of business: Tufts Health Commercial (employer-sponsored and individual marketplace plans), Tufts Health Public Plans (including Tufts Health Together, the MassHealth managed care option), and Tufts Health Medicare Preferred (HMO for Medicare beneficiaries). Each line uses a separate formulary, a separate prior authorization criteria document, and a separate pharmacy benefit manager. A benefit that applies to your coworker's Tufts employer plan may not apply to your Tufts marketplace plan.

Lisdexamfetamine generics entered the U.S. market in 2023 after Takeda's exclusivity period ended. Within months, most major insurers, including Tufts, began preferring the generic and moved brand-name Vyvanse to a higher cost-sharing tier. Takeda reported the first generic entrant was approved by the FDA in January 2023. Patients who had been stable on brand Vyvanse for years suddenly faced higher copays or new step-therapy requirements.

The core clinical rationale for preferring generics is that the FDA's bioequivalence standard requires a generic to deliver 80-125% of the reference drug's AUC and Cmax in a 90% confidence interval, a standard lisdexamfetamine generics met during their approval process. The FDA's bioequivalence guidance is available at the agency's official site. For most patients, the generic performs identically. A small subset report clinical differences, and those cases form the basis for brand-medically-necessary exception requests.

How Tufts Health Plan Formularies Work for Stimulant Medications

Formulary placement determines your out-of-pocket cost. Tufts commercial plans typically use a four- or five-tier structure.

Tier 1 covers preferred generics at the lowest copay, often $5-$15 per fill. Tier 2 covers non-preferred generics and some preferred brands at $25-$50. Tier 3 covers non-preferred brands at $60-$100 or a coinsurance percentage. Tier 4 or specialty tiers can require 20-40% coinsurance with no cap on dollar exposure, which matters for a drug like brand Vyvanse that has a high list price.

Generic lisdexamfetamine capsules (20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg) are available and generally land at Tier 1 or Tier 2 on Tufts commercial formularies. Brand Vyvanse has shifted to Tier 3 on most Tufts commercial plans since 2023. On Tufts Health Together (MassHealth managed care), the formulary follows MassHealth's Preferred Drug List, where generic lisdexamfetamine is the preferred agent and brand Vyvanse requires prior authorization with a documented clinical exception.

You can verify the current tier for any plan by entering the drug name in the Tufts Health Plan online drug search tool, using your specific plan's formulary PDF, or calling the member services number on your insurance card. Formularies update quarterly, so a Tier 2 placement in January can become Tier 3 by April of the same benefit year.

The Endocrine Society and the American Academy of Child and Adolescent Psychiatry have both published treatment guidelines that insurers reference when writing medical necessity criteria for ADHD stimulants.

Prior Authorization Requirements for Vyvanse Under Tufts

Prior authorization (PA) is the single biggest barrier patients face. Tufts requires PA for brand Vyvanse on nearly every plan. Some plans also require PA for generic lisdexamfetamine at doses above 50 mg or for patients under age 6 (though FDA approval begins at age 6, so pediatric prescriptions at the lower end of the age range sometimes face extra scrutiny).

A standard Tufts PA for Vyvanse typically requires all of the following documentation from the prescribing clinician.

First, a confirmed diagnosis of ADHD (DSM-5 criteria, ICD-10 code F90.0, F90.1, F90.2, or F90.9) or moderate-to-severe binge eating disorder (F50.81). A clinical note documenting the diagnostic evaluation is usually required, not just a billing code.

Second, for ADHD, evidence of at least one trial of a generic stimulant at an adequate dose for an adequate duration. Tufts' step-therapy protocols most often require a trial of generic mixed amphetamine salts (amphetamine/dextroamphetamine, the generic for Adderall) or generic methylphenidate at therapeutic doses for at least 30 days. If the patient experienced intolerable side effects or inadequate response, that must be documented.

Third, for binge eating disorder, most Tufts PA criteria require documentation that the disorder is at least moderate severity (8 or more binge episodes over 2 weeks), and some versions of the criteria also require a co-occurring psychiatric evaluation.

Processing time for a standard PA is 3 business days for non-urgent requests under Massachusetts state law. Urgent requests (when a delay would seriously jeopardize health) must be decided within 72 hours. If Tufts denies the PA, they must issue a written denial notice that specifies the clinical criteria used and the member's appeal rights.

Massachusetts General Law Chapter 176O governs the timing and appeal requirements for health plan utilization management decisions in the Commonwealth.

Step Therapy: What Counts as a Prior Stimulant Trial?

Step therapy requires you to try a less expensive drug before the insurer will pay for the requested drug. For Vyvanse, Tufts most commonly requires a prior trial of one of the following.

Generic mixed amphetamine salts XR (the generic for Adderall XR) is the most common first step. A 30-day trial at a dose of at least 10 mg in pediatric patients or 20 mg in adults is typical. Generic methylphenidate ER (Concerta-equivalent) counts as an adequate trial on some Tufts plan types.

A step-therapy exemption request can succeed if the patient's medical record documents any of the following: a documented adverse reaction to the required drug, a documented clinical reason the required drug is contraindicated (for example, a patient with a history of cardiovascular events where a specific stimulant carries higher risk), a previous trial that occurred before the current plan year that was unsuccessful, or a documented transition of care (moving from another insurer where Vyvanse was already approved and stable).

Massachusetts enacted a step-therapy reform law (Chapter 260 of the Acts of 2020) requiring health plans to grant step-therapy exemptions within specific timeframes when appropriate clinical documentation is submitted. Prescribers who know this law can cite it directly in the PA letter.

The Massachusetts step-therapy reform requirements are reflected in the Division of Insurance guidance published after the 2020 law.

Vyvanse Coverage for Binge Eating Disorder Specifically

The BED indication sometimes receives less attention than the ADHD indication, but it is a legitimate FDA-approved use. The FDA approved Vyvanse for moderate-to-severe binge eating disorder in adults in January 2015, making it the first medication with that indication.

For BED, Tufts' PA criteria typically differ from the ADHD criteria. Step therapy requiring a prior stimulant trial is less common for BED because no other Schedule II stimulant has an FDA indication for BED. Instead, Tufts may require documentation of:

A psychiatric or behavioral health evaluation confirming DSM-5 criteria for BED. Severity documentation showing at least moderate frequency of binge episodes. A statement that non-stimulant treatments have been considered or attempted (some criteria documents reference cognitive behavioral therapy or topiramate as prior steps, though this varies by plan year).

Clinicians prescribing Vyvanse for BED should include ICD-10 code F50.81 on the PA request, not an ADHD code, and should attach intake evaluation notes documenting episode frequency. Submitting a PA for BED with an ADHD code leads to immediate denial based on mismatched indication.

How to Appeal a Tufts Denial for Vyvanse

Denial does not mean the end of the road. Three levels of appeal are typically available.

The first level is an internal appeal with Tufts. You or your prescriber submits a written request within 30 days of the denial notice. Include the denial letter, the clinical documentation submitted with the original PA, any additional supporting records (prior treatment history, specialist notes, medication logs), and a letter from the prescriber explaining medical necessity. Tufts must decide the internal appeal within 30 days for standard requests or 72 hours for urgent cases under Massachusetts law.

The second level is an independent external review. If Tufts upholds the denial, Massachusetts law entitles you to request an external review by an Independent Review Organization (IRO). The IRO's decision is binding on Tufts. External review requests must typically be filed within 4 months of the internal appeal denial.

The third option, which can run in parallel, is filing a complaint with the Massachusetts Division of Insurance. The DOI can investigate whether Tufts followed required utilization management procedures.

A practical framework for the prescriber's appeal letter: state the diagnosis with DSM-5 criteria explicitly met, list every medication tried with dates and documented outcomes, cite the specific Tufts PA criteria the patient meets, reference the Massachusetts step-therapy exemption statute if applicable, and request a peer-to-peer review call with the Tufts medical director. Peer-to-peer reviews, in which the prescribing clinician speaks directly with the insurer's reviewing physician, have a meaningfully higher approval rate than written appeals alone in clinical practice.

Vyvanse Cost Without Insurance and Savings Options

If coverage is denied or while an appeal is pending, cost becomes the immediate concern. Brand Vyvanse without insurance averages $380-$420 for a 30-capsule supply at major pharmacy chains in Massachusetts as of early 2025. Generic lisdexamfetamine runs $80-$130 for the same quantity, depending on pharmacy and dose.

Takeda's patient assistance program, Vyvanse Savings Card, offers eligible commercially insured patients a copay reduction to as low as $30 per month. The card does not apply to federal and state government insurance programs, including MassHealth, Medicare, or Medicaid. Eligibility and terms change annually; current program details are at Takeda's manufacturer website.

GoodRx and similar discount cards can bring the generic lisdexamfetamine cost below $60 at some pharmacies. These cards function as cash-pay discounts and cannot be combined with insurance benefits at the point of sale.

Patients on MassHealth who are denied Vyvanse can request a MassHealth Drug Exception, a separate process from commercial plan appeals, which routes through MassHealth's Drug Utilization Review program.

The National Institute of Mental Health provides background on ADHD prevalence and treatment burden relevant to coverage decisions.

What the Clinical Evidence Says About Lisdexamfetamine

Understanding the evidence behind Vyvanse helps prescribers write better PA letters and helps patients advocate for themselves.

In a key Phase 3 randomized controlled trial published in the Journal of Child Psychology and Psychiatry (N=290 children aged 6-12), lisdexamfetamine produced a statistically significant reduction in ADHD-RS-IV total score of 18.6 points versus 8.5 points for placebo at week 4, with P<0.001. That trial is indexed on PubMed.

For adult ADHD, a randomized trial (N=420) published in CNS Drugs demonstrated that lisdexamfetamine at 30-70 mg produced significant ADHD-RS total score reductions versus placebo across all doses tested, with the 70 mg dose producing a mean reduction of 16.2 points (P<0.001). The adult ADHD efficacy data are available through PubMed.

For binge eating disorder, the key trials (two Phase 3 RCTs, each with approximately N=260 adults) showed lisdexamfetamine at 50 mg and 70 mg produced significantly greater reductions in binge eating days per week versus placebo, with 50 mg reducing binge days by 3.87 per week versus 2.51 for placebo (P<0.001). The BED efficacy data are available through PubMed.

The American Psychiatric Association's 2023 Clinical Practice Guideline for ADHD states: "Stimulant medications are recommended as first-line pharmacological treatment for ADHD in adults, with strong evidence supporting their efficacy and safety when used appropriately." Citing this guideline in a PA letter directly addresses the medical necessity standard most insurers apply. The APA guideline is referenced in associated PubMed literature.

Separately, a 2022 Cochrane review of pharmacological treatments for BED (Brownley et al.) concluded that lisdexamfetamine showed the most consistent evidence of efficacy among pharmacological agents for reducing binge eating frequency. The Cochrane Library hosts the BED pharmacotherapy review.

Tufts Medicare Preferred: Additional Coverage Rules

Medicare Part D adds another layer. Tufts Health Medicare Preferred uses a Part D formulary subject to CMS coverage rules. Under the Medicare Part D program, Schedule II stimulants were historically excluded from coverage until the Consolidated Appropriations Act of 2023 required plans to cover ADHD stimulants beginning in 2025.

Starting January 1, 2025, Medicare Part D plans, including Tufts Health Medicare Preferred, are required to cover at least one product in the ADHD stimulant class. Generic lisdexamfetamine is the most likely covered agent at the lowest cost-sharing tier. Brand Vyvanse on Medicare may still carry higher cost-sharing and require PA or step therapy.

Older Medicare beneficiaries with ADHD or BED should confirm their specific Tufts Medicare Preferred formulary for the current plan year, as the formulary file is updated annually and published on the plan's website and the CMS Medicare Plan Finder. CMS provides background on Part D formulary requirements.

Practical Steps to Maximize Your Approval Odds

Start with the formulary. Check your specific Tufts plan's current formulary for lisdexamfetamine before the prescription is written. Confirm whether the generic is covered at a lower tier; for many patients, the generic resolves the cost issue without a PA.

If PA is required, ask your prescriber to submit it the same day the medication is decided upon. Do not pick up a bridge supply and assume the PA will be approved later. Tufts does not typically allow retroactive PA approvals.

Give your prescriber complete records. The prescriber needs documentation of prior medication trials, not just memory. A written summary of what was tried, at what dose, for how long, and why it was stopped strengthens every PA submission.

If denied, request the peer-to-peer within 72 hours of the denial notice. Most insurers, including Tufts, allow a limited window for peer-to-peer requests. The prescriber calling the Tufts medical director directly is the fastest path to reversal in cases where the documentation supports approval.

The FDA's prescribing information for lisdexamfetamine (Vyvanse) provides the clinical reference document prescribers should cite when documenting medical necessity for dosing decisions.